Fundz

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

PUBLIC · HOWLApr 17, 2025

Position

Chief Business Officer

Company

Werewolf Therapeutics

Steven Bloom
sbloom@werewolftx.com
WatertownBiotechnologyHealthcareHealth CareTherapeutics

Description

Werewolf Therapeutics, Inc. has appointed Steven Bloom as Chief Business Officer, bringing over 35 years of experience in the life sciences industry. His expertise is expected to advance Werewolf's innovative cancer treatment technologies.

Who to call at Werewolf Therapeutics, and when

A new leader at Werewolf Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Werewolf Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Werewolf Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Werewolf Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Werewolf Therapeutics

Location

200 Talcott Ave, 2nd Floor

Watertown, Massachusetts, United States

About

Werewolf Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATORTM platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINETM molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) in multiple solid tumor types. WTX-330 is in development as a single agent in refractory and/or immunotherapy unresponsive or resistant advanced or metastatic solid tumors and non-Hodgkin lymphoma.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Werewolf Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Dan
Senior decision-maker at this company
••••••••@••••••••

See Dan's verified email →

Steven
Likely contact at this company
••••••••@••••••••

See Steven's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Werewolf Therapeutics's next move

Learn about Strategic plan

Werewolf Therapeutics changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.